HIV-1 p24 Antikörper

Produktnummer ABIN7849765

Der Maus Monoklonal anti-HIV-1 p24 Antikörper wird verwendet zum Nachweis von HIV-1 p24 in Proben von Human. Er wurde validiert für ELISA.

Kurzübersicht für HIV-1 p24 Antikörper (ABIN7849765)

Target: HIV-1 p24 (Human Immunodeficiency Virus 1 Capsid (HIV-1 p24))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser HIV-1 p24 Antikörper ist unkonjugiert

Applikation: ELISA

Klon: B8

Produktdetails anti-HIV-1 p24 Antikörper

Verwendungszweck: Monoclonal Anti- HIV-1 p24 (Capture Ab)

Produktmerkmale: This antibody may be used as Capture Ab in antibody pair experiments such as ELISA.

Aufreinigung: Protein A or G purified

Reinheit: >95 % by HPLC & SDS-PAGE

Immunogen: Recombinant human HIV-1 p24 Protein (Expression system with E.Coli).

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: 0.9 % NaCl without preservative.

Konservierungsmittel: Without preservative

Handhabung: Avoid repeated freeze and thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: Aliquot and store at -20°C for long term (at least for one year). Avoid repeated freeze and thaw cycles.

Haltbarkeit: 12 months

Details zu HIV-1 p24

Target: HIV-1 p24 (Human Immunodeficiency Virus 1 Capsid (HIV-1 p24))

Andere Bezeichnung: HIV-1 p24

Substanzklasse: Viral Protein

Hintergrund: Acquired immune deficiency syndrome (HIV/AIDS) has been a major global health concern for over 38 years. No safe and effective preventive or therapeutic vaccine has been developed although many products have been investigated. Computational methods have facilitated vaccine developments in recent decades. Among HIV-1 proteins, p24 and Nef are two suitable targets to provoke the cellular immune response. The predicted fusion protein, p24-AAY-Nef in a truncated form with a high rate of T cell epitopes and high conservancy rate among different clades, provides a helpful model for developing a therapeutic vaccine candidate against HIV-1. HIV-1 infection of macrophages leads to the sequestration of newly formed viruses in intracellular plasma membrane-connected structures termed virus-containing compartments (VCCs), where virions remain infectious and hidden from immune surveillance. HIV-1 infection of macrophages leads to the sequestration of newly formed viruses in virus-containing compartments (VCCs), where virions remain infectious and hidden from immune surveillance. The transmembrane domain of Vpu and two motifs of the Vpu cytoplasmic domain are required for these functions. These motifs were notably involved in the control of the volume of VCCs by Vpu but were dispensable for the prevention of the specific accumulation of BST2 in these structures.